痰热清注射液联合孟鲁司特治疗慢性阻塞性肺疾病急性加重期患者的疗效观察  

Clinical Observation of Tanreqing Injection Combined with Montelukast in the Treatment of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

作　　者：孙颖[1] 张玉龙[1] 毛文娟[2] 刘莉 韩月肖 SUN Ying~, ZHANG Yu-long1, MAO Wen-juan2, LIU L？, HAN Yue-xiao4(1Department of Respiratory, Baoji Hospital of Traditional Chinese Medicine, Baoji, Shaanxi, 721000, China; 2 Department of Cardiology, Jintai Hospital o fBaoji, Baoji, Shaanxi, 721000, China; 3 Department of Geriatrics, Xianyang Central Hospital, Xianyang, Shaanxi, 712000, China; 4 Department of Intensive Care Medicine, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Baoji, Shaanxi, 721000, Chin)

机构地区：[1]宝鸡市中医医院呼吸科,陕西宝鸡721000 [2]宝鸡市金台医院心内科,陕西宝鸡721000 [3]咸阳市中心医院老年科,陕西咸阳712000 [4]陕西省中医医院重症医学科,陕西宝鸡721000

出　　处：《现代生物医学进展》2018年第3期541-544,564,共5页Progress in Modern Biomedicine

摘　　要：目的:探讨痰热清注射液联合孟鲁司特治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者的疗效。方法:将2014年5月至2016年12月我院收治的AECOPD患者116例按照随机数字表法分为研究组和对照组,每组58例,对照组患者给予AECOPD常规治疗,同时口服孟鲁司特10 mg/d,研究组则在此基础上静脉滴注痰热清注射液20 mL/d,两组疗程均为2周。观察两组临床疗效、患者临床症状改变,并对比两组治疗前后血清白细胞介素-6(IL-6)、白细胞介素-8(IL-8)和肿瘤坏死因子-α(TNF-α)水平。结果:研究组总有效率为98.28%,明显高于对照组的87.93%(P<0.05)。研究组患者咳嗽消失时间、气促消失时间、哮鸣音消失时间明显低于对照组(P<0.05)。治疗后两组患者血清IL-6、IL-8以及TNF-α水平均降低(P<0.05),且研究组较对照组降低(P<0.05)。结论:痰热清注射液联合孟鲁司特治疗AECOPD能够有效缓解患者症状,降低患者炎症反应,临床效果较好。Objective： To observe the clinical efficacy of Tanreqing injection combined with montelukast in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. Methods： 116 patients with AECOPD in our hospital from May 2014 to December 2016 were randomly divided into study group and control group, 58 cases in each group, the control group were treated with AECOPD conventional treatment, oral montelukast 10 mg/d, study group were treated with intravenous dripping Tanreqing injection 20 mL/d on the basis of the control group, and two groups were treated for 2 weeks. The clinical efficacy, clinical symptoms change of two groups were observed, and the levels of serum interleukin-6（IL-6）, interleukin-8（IL-8） and tumor necrosis factor-α（TNF-α） were compared between the two groups before and after treatment. Results： The total effective rate of the study group was98.28%, which was significantly higher than that of the control group（87.93%）（P〈0.05）. The disappearance time of cough, shortness of breath, wheezing in study group were significantly lower than the control group（P〈0.05）. There was no significant difference in serum IL-6, IL-8 and TNF-α levels between the two groups before treatment（P〉0.05）. After treatment, the serum levels of IL-6, IL-8 and TNF-α were significantly decreased in the two groups（P〈0.05）, and the serum levels of IL-6, IL-8 and TNF-α in the study group were significantly lower than those in the control group（P〈0.05）. Conclusion： Tanreqing injection combined with montelukast can effectively alleviate the symptoms of patients with AECOPD, reduce the inflammatory response of patients, the clinical effect is better.

关 键 词：慢性阻塞性肺疾病 痰热清注射液 孟鲁司特 临床疗效 

分 类 号：R563[医药卫生—呼吸系统]